SuperworthHarmony Biosciences EPS HRMY
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- $3.09
- Latest quarter, Q2 FY26
- $1.28
- +88% on a year earlier
- Fiscal year 2025
- $2.72
- +8% on the year before
Harmony Biosciences' earnings per share was $3.09 over the twelve months to Jun 30, 2026, down 0% on a year earlier.
In its latest quarter, Q2 FY26, it was $1.28, up 88% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $2.72 | +8% |
| FY2024 | $2.51 | +18% |
| FY2023 | $2.12 | −29% |
| FY2022 | $2.97 | +412% |
| FY2021 | $0.58 | n/a |
| FY2020 | −$7.78 | n/a |
| FY2019 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.28 | +88% | $3.09 | |
| Q1 FY26 | $0.55 | −29% | $2.49 | |
| Q4 FY25 | $0.39 | −54% | $2.72 | |
| Q3 FY25 | $0.87 | +10% | $3.18 | |
| Q2 FY25 | $0.68 | +240% | $3.10 | |
| Q1 FY25 | $0.78 | +16% | $2.62 | |
| Q4 FY24 | $0.85 | +89% | $2.51 | |
| Q3 FY24 | $0.79 | +25% | $2.11 | |
| Q2 FY24 | $0.20 | −64% | $1.95 | |
| Q1 FY24 | $0.67 | +40% | $2.31 | |
| Q4 FY23 | $0.45 | −43% | $2.12 | |
| Q3 FY23 | $0.63 | −56% | $2.46 |
Against its peers
Companies in Drug Manufacturers - General nearest Harmony Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| NRIXNurix Therapeutics | $2.31 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| OGNOrganon | $0.77 | −71% a year |
| OMEROmeros | $1.52 | |
| LQDALiquidia | $1.39 | |
| ARQTArcutis Biotherapeutics | $0.22 | |
| Peer median | $1.92 |
Where Harmony Biosciences ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Harmony Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.